Susvimo 10 MG/0.1 ML vial 0.1ML
Ended Awarded
- Contract number
- SPE2DR26FQWC4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,164
Award facts
- Contract value 100% obligated
- $11,164.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $11,164.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Susvimo 10 mg/0.1 mL vials. The delivery order, awarded on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This delivery order is issued under the company's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract, a $499.999 billion initiative awarded to DMS Pharmaceutical Group on November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense military healthcare facilities worldwide through December 31, 2036.
The PPV-G GEN V contract represents part of the Defense Logistics Agency's broader $30.3 billion acquisition strategy to ensure reliable pharmaceutical supply chains supporting military medical operations globally. DMS Pharmaceutical Group's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables across multiple therapeutic categories. The company's established performance on numerous previous delivery orders and its status as a single-award regional prime vendor contractor under PPV-G GEN V demonstrate its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system with no identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DR26FQWC4?
SPE2DR26FQWC4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FQWC4 worth?
The government has obligated $11,164 on SPE2DR26FQWC4.
Is contract SPE2DR26FQWC4 an order under another contract?
Yes. SPE2DR26FQWC4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWC4 competed?
The extent of competition for SPE2DR26FQWC4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award